New 10-12.5% Tariffs on 60 Trading Partners Upend Supply Chain Planning

Supply chain leaders are scrambling to decode the new tariff matrix, which abruptly shifts from a blanket 10% duty to a complex two-tier system on the 60 countries that supply the vast majority of U.S. imports. With immediate fees on Canadian goods and threats against pharma, the cost of cross-border logistics is set for another volatile chapter that will demand agile supplier diversification and robust compliance infrastructure.

In a defiant move following the Supreme Court's February 2026 ruling striking down his preferred tariff authority under the International Emergency Economic Powers Act (IEEPA), President Trump has restructured U.S. trade policy with a new two-tier tariff system. Effective July 24, 2026, a temporary global 10% tariff expired and was immediately replaced by duties of 10% and 12.5% on goods from the 60 largest U.S. trading partners—59 individual nations plus the European Union. The administration simultaneously announced new fees on Canadian imports and threatened future tariffs on pharmaceuticals, signaling an unwavering commitment to protectionist measures.

“

Effective July 24, 2026, a temporary global 10% tariff expired and was immediately replaced by duties of 10% and 12.5% on goods from the 60 largest U.S.

The legal backdrop is critical: on February 20, the Supreme Court invalidated the IEEPA-based tariff regime, deeming it an overreach. Within hours, the president vowed to use alternative statutory authorities, and soon after imposed a blanket 10% tariff designed to expire once a more permanent structure was ready. That temporary duty ended at midnight on July 24, giving way to the current framework. The new system avoids the sweeping single-rate approach, instead categorizing the 60 most significant trade partners into two tiers, likely based on trade balances, strategic relationships, or perceived unfair practices, though the exact criteria remain opaque.

The immediate practical effect is a complex compliance landscape for importers. Unlike the global tariff that applied uniformly, the two-tier structure requires classifying goods by country of origin across a much wider set of rates—10% for some partners, 12.5% for others. This complicates customs documentation, supply chain planning, and cost forecasting. Canada, a top-three trading partner, faces additional, unspecified fees on top of the tiered duties, threatening deeply integrated cross-border supply chains in automotive, energy, and agriculture. The threat of pharmaceutical tariffs adds another layer of uncertainty for a sector already navigating drug pricing reforms and fragile global supply networks.

Economically, the tariffs represent a significant tax on imported goods, with an estimated $2.5 trillion in annual trade now subject to elevated duties. U.S. businesses, particularly retailers and manufacturers reliant on intermediate goods from the targeted countries, face immediate margin compression. Higher input costs are likely to be passed to consumers, reigniting inflation concerns that had begun to ease. The Federal Reserve, which had signaled a potential easing cycle, now confronts a stagflationary risk—higher prices coupled with slowing trade-driven growth.